Literature DB >> 9559811

Fluconazole pharmacokinetics in burn patients.

B A Boucher1, S R King, H L Wandschneider, W L Hickerson, S D Hanes, V L Herring, T W Canada, M M Hess.   

Abstract

The pharmacokinetics of fluconazole in nine adult patients with severe (30 to 95% total body surface area) burns were studied. There was no significant difference in half-life (t1/2), clearance (CL), or volume of distribution (V) over time in five patients on days 3 and 8 of the study (P > 0.05). Combined parameter estimates (means +/- standard deviations) for all nine patients for the two study periods were as follows: t1/2, 24.4 +/- 5.8 h; CL, 0.36 +/- 0.09 ml/min/kg; and V, 0.72 +/- 0.12 liters/kg. These estimates of t1/2 and CL in burn patients were approximately 13% shorter and 30% more rapid, respectively, than the most extreme estimates reported for other populations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559811      PMCID: PMC105570          DOI: 10.1128/AAC.42.4.930

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients.

Authors:  R J Sawchuk; D E Zaske
Journal:  J Pharmacokinet Biopharm       Date:  1976-04

2.  Pharmacokinetics of fluconazole in normal volunteers.

Authors:  S Ripa; L Ferrante; M Prenna
Journal:  Chemotherapy       Date:  1993       Impact factor: 2.544

3.  Increased glomerular filtration rate in patients with major burns and its effect on the pharmacokinetics of tobramycin.

Authors:  P Loirat; J Rohan; A Baillet; F Beaufils; R David; A Chapman
Journal:  N Engl J Med       Date:  1978-10-26       Impact factor: 91.245

4.  Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection.

Authors:  P Bourget; A Lesne-Hulin; R Le Reveillé; H Le Bever; H Carsin
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 5.  Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.

Authors:  V J Fraser; M Jones; J Dunkel; S Storfer; G Medoff; W C Dunagan
Journal:  Clin Infect Dis       Date:  1992-09       Impact factor: 9.079

Review 6.  Clinical pharmacokinetics of fluconazole.

Authors:  D Debruyne; J P Ryckelynck
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

7.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute.

Authors:  J H Rex; J E Bennett; A M Sugar; P G Pappas; C M van der Horst; J E Edwards; R G Washburn; W M Scheld; A W Karchmer; A P Dine
Journal:  N Engl J Med       Date:  1994-11-17       Impact factor: 91.245

8.  Increased dosage requirements of gentamicin in burn patients.

Authors:  D E Zaske; R J Sawchuk; D N Gerding; R G Strate
Journal:  J Trauma       Date:  1976-10

Review 9.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

10.  The necessity of increased doses of amikacin in burn patients.

Authors:  D E Zaske; R J Sawchuk; R G Strate
Journal:  Surgery       Date:  1978-11       Impact factor: 3.982

View more
  11 in total

1.  [Not Available].

Authors:  Jf Arnould; R Le Floch
Journal:  Ann Burns Fire Disasters       Date:  2015-03-31

2.  Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury.

Authors:  Tyree H Kiser; Dorie W Hoody; Marilee D Obritsch; Colleen O Wegzyn; Paulus C Bauling; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with Candida infection.

Authors:  Seunghoon Han; Jimyon Kim; Haejun Yim; Jun Hur; Wonkeun Song; Jongtae Lee; Sangil Jeon; Taegon Hong; Heungjeong Woo; Dong-Seok Yim
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

4.  Comparison of the pharmacokinetics of linezolid in burn and non-burn rabbits.

Authors:  Jian-Li Ma; Lei Gao; Xiang Li; Wan-Li Chu; Yong-Qiang Feng; Xiao-Qin Wang; Qing-Zhe Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-06-13       Impact factor: 2.441

5.  Micafungin concentrations in the plasma and burn eschar of severely burned patients.

Authors:  Junichi Sasaki; Satoshi Yamanouchi; Daisuke Kudo; Tomoyuki Endo; Ryosuke Nomura; Kiyotsugu Takuma; Shigeki Kushimoto; Yotaro Shinozawa; Satoshi Kishino; Shingo Hori; Naoki Aikawa
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  Evaluation of Voriconazole and Posaconazole Dosing in Patients With Thermal Burn Injuries.

Authors:  Kaitlin L Musick; Savannah L Jones; Ashlyn M Norris; Lauren J Hochstetler; Felicia N Williams; Brian P McKinzie
Journal:  J Burn Care Res       Date:  2022-07-01       Impact factor: 1.819

7.  Fluconazole plasma concentration measurement by liquid chromatography for drug monitoring of burn patients.

Authors:  Silvia Regina Cavani Jorge Santos; Edvaldo Vieira Campos; Cristina Sanches; David Souza Gomez; Marcus Castro Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

8.  Comparative Population Plasma and Tissue Pharmacokinetics of Micafungin in Critically Ill Patients with Severe Burn Injuries and Patients with Complicated Intra-Abdominal Infection.

Authors:  A García-de-Lorenzo; S Luque; S Grau; A Agrifoglio; L Cachafeiro; E Herrero; M J Asensio; S M Sánchez; J A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

Review 9.  Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients.

Authors:  Benoit Blanchet; Vincent Jullien; Christophe Vinsonneau; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

10.  Penetration of micafungin into the burn eschar in patients with severe burns.

Authors:  Junichi Sasaki; Satoshi Yamanouchi; Yukio Sato; Shinya Abe; Yotaro Shinozawa; Satoshi Kishino; Naoki Aikawa; Shingo Hori
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-06-15       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.